References for Adjuvant Therapy for Breast Cancer
- Alvarez RH, Valero V, Hortobagyi GN. (2010) Emerging targeted therapies for breast cancer. J Clin Oncol. (July 2010) 28(20):3366-79. Epub 2010 Jun 7. https://www.ncbi.nlm.nih.gov/pubmed/20530283
- Baxevanis CN, Perez SA, Papamichail M. (2009) Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother. 2009;58(3):317–324. https://www.ncbi.nlm.nih.gov/pubmed/18704409
- Clarke M, Collins R, Darby S. (et al). (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. (2005);366(9503):2087–2106. https://www.ncbi.nlm.nih.gov/pubmed/16360786
- Dent R, Trudeau M, Pritchard KI. (et al). (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–4434 https://www.ncbi.nlm.nih.gov/pubmed/17671126
- Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717 https://www.ncbi.nlm.nih.gov/pubmed/15894097
- Ellis MJ, Tao Y, Luo J. (et al). (2008) Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J. Natl Cancer Inst. (2008)100(19), 1380–1388 https://www.ncbi.nlm.nih.gov/pubmed/18812550
- Fisher B, Anderson S, Tan-Chiu E. (et al). (2001) Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931-942 https://www.ncbi.nlm.nih.gov/pubmed/11181655
- Hortobagyi GN, Spanos W, Montague ED. (et al). (1983) Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys. 1983;9(5):643–650. https://www.ncbi.nlm.nih.gov/pubmed/6343312
- Larinov AA, Miller WR. (2009) Challenges in Defining Predictive Markers for Response to Endocrine Therapy in Breast Cancer . Future Oncology. 2009;5(9):1415-1428 https://www.ncbi.nlm.nih.gov/pubmed/19903069
- Lo YH, Ho PC, Zhao H, Wang SC. Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016). Anticancer Res. (March 2011)31(3):789-95. https://www.ncbi.nlm.nih.gov/pubmed/21498698
- Ma CX, Ellis MJ. (2006) Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin. Oncol. (2006)33(6), 650–656. https://www.ncbi.nlm.nih.gov/pubmed/17145344
- Mittendorf EA, Peoples GE, Singletary SE. (2007) Breast cancer vaccines: promise for the future or pipe dream? Cancer. 2007;110(8):1677–1686. https://www.ncbi.nlm.nih.gov/pubmed/17763371
- Soliman, H. (2010) Developing an Effective Breast Cancer Vaccine. Cancer Control. 2010;17(3):183-190. https://www.ncbi.nlm.nih.gov/pubmed/20664516
